Results 151 to 160 of about 22,312 (181)

Invasive neonatal candidiasis: an overview

Seminars in Perinatology, 2003
Until the 1980s, recovery of Candida species from normally sterile body sites in high-risk infants was often dismissed as contamination. Such delay in diagnosis often resulted in death, multifocal disease, or significant morbidity, outcomes that still occur today.
Rachel L, Chapman, Roger G, Faix
openaire   +2 more sources

Invasive Candidiasis During Granulocytopenia

1993
Candidiasis remains the most frequently encountered fungal infection in patients with profound granulocytopenia and appears to be increasing in frequency. In addition, Candida infections are occurring earlier during remission induction chemotherapy and can be caused by a variety of species such as C. albicans, C. tropicalis, and C. krusei.
E, Anaissie, H, Pinczowski
openaire   +2 more sources

The Role of the Laboratory in the Diagnosis of Invasive Candidiasis

Drugs, 2009
A diagnosis of invasive candidiasis can be achieved using conventional approaches (microscopy, culture, serology), as well as new methods, including antigen detection and polymerase chain reaction (PCR) assays. Most of the conventional approaches lack sensitivity, especially for obtaining a diagnosis of invasive candidiasis in immunocompromised ...
M. T. Montagna, R. Iatta, E. Borghi, G. Morace   +3 more
openaire   +4 more sources

Invasive candidiasis in neonates and children

Early Human Development, 2011
Invasive candidiasis is associated with high morbidity and mortality in neonates and children. The incidence of invasive candidiasis is greater in children than in adults and is particularly high in neonates. Main risk factors are multiple antibiotics, central venous catheters, parenteral nutrition, immunodepression, low birth weight, fungal ...
openaire   +2 more sources

Rezafungin: A Review in Invasive Candidiasis

Drugs
Rezafungin (Rezzayo®) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intravenous administration. It has recently been approved for the treatment of adults with invasive candidiasis in the EU and UK, and is approved for adults ...
Simon Fung, Matt Shirley
openaire   +2 more sources

Serodiagnosis of Invasive Candidiasis

Annals of the New York Academy of Sciences, 1988
L S, Young, P R, Stevens
openaire   +2 more sources

Invasive Candidiasis in Asia

2019
This chapter provides an overview on the epidemiology of invasive candidiasis in Asia highlighting the unique features of Candida tropicalis, a common Candida species of particular importance in Asia, and Candida auris, a recently emerging multidrug-resistant Candida species, which was first reported from Asia and has caused public health impact ...
openaire   +1 more source

Immunology of Invasive Candidiasis

2014
Invasive candidiasis is a life-threatening opportunistic infection and has emerged as a major cause of morbidity and mortality in critically ill patients. Until recently, Candida albicans was by far the predominant species, causing up to two-thirds of all cases of invasive candidiasis.
openaire   +2 more sources

An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date

Expert Opinion on Pharmacotherapy, 2021
Rhonda E Colombo
exaly  

T-cells of invasive candidiasis patients show patterns of T-cell-exhaustion suggesting checkpoint blockade as treatment option

Journal of Infection, 2022
Sibylle C Mellinghoff, Martin Thelen, Jonas Lehmann   +2 more
exaly